The 12th Annual ALS TDI Tri-State Trek to End ALS to Ride June 27-29

Share Article

Proceeds from the three-day, 270-mile bicycle ride to benefit drug development for Lou Gehrig’s disease.


2014 ALS TDI Tri-State Trek

The ALS Therapy Development Institute (ALS TDI) announced today that its 12th annual ALS TDI Tri-State Trek charity cycling event will be held on Friday, June 27 to Sunday, June 29. The ALS TDI Tri-State Trek is a three-day, 270-mile bicycle ride with the purpose of fundraising for ALS TDI in its mission to discover and develop effective treatments to end amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

The ALS TDI Tri-State Trek is a fully supported event where riders cycle a marked course at their own pace, with rest stops every 15-20 miles. The first day’s course is 100 miles; the second day’s route is 90 miles; and the last day’s total is 80 miles. This year, participants start from Boston College in Chestnut Hill, MA, overnight in college dormitories at both the University of Connecticut in Storrs and then the University of New Haven, and finish at Roger Sherman Baldwin Park in Greenwich, CT.

The event offers cyclists the option to ride one, two, or all three days of the event, as well as an 18-mile ride alternative called the “Greenwich Police Sgt. Roger Petrone Ride” on Sunday, June 29. That ride will start at the Boys & Girls Club of Greenwich and end at the ALS TDI Tri-State Trek’s Greenwich finish line at Roger Sherman Baldwin Park.

The ALS TDI Tri-State Trek began in 2003 with 16 cyclists, and this year, expects an estimated 350 participants. The event has raised more than $5 million for ALS TDI, the world’s largest ALS-dedicated drug development organization located in Cambridge, MA. ALS TDI has tested more potential treatments for ALS than any other research lab, thanks to support from fundraising events like the ALS TDI Tri-State Trek. The Institute’s lead ALS therapeutic candidate, Novartis’ (Switzerland) Gilenya (TDI-132), is being investigated through a Phase II clinical trial, and the Institute is currently raising funds to advance two other clinical candidates into patients as well as establish the world’s first ALS dedicated personalized medicine center.

“The ALS TDI Tri-State Trek is challenging physically and mentally, but there is a feeling of empowerment at the end of each day knowing you are pushing your own limits to fight this devastating disease,” says Steve Perrin, Ph.D., CEO and Chief Scientific Officer of ALS TDI and a three-day cyclist in the Tri-State Trek. “This event is critical in funding research projects at ALS TDI, enabling our scientists to continue making discoveries that will one day lead to effective treatments and a cure for Lou Gehrig’s disease.”

For more information and to register, visit or call 617-441-7200.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to discover and develop effective treatments for ALS patients today as soon as possible. ALS TDI is the world’s largest independent ALS/MND drug development-focused nonprofit organization. In addition to more than 30 internal therapeutic aimed programs, the world’s first nonprofit biotech partners with dozens of pharmaceutical and biotechnology companies worldwide in order to advance potential treatments into the clinic. Its lead ALS therapeutic candidate, Novartis’ (Switzerland) Gilenya (TDI-132), is in Phase 2A clinical trial for ALS. For more information on its drug development programs, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mari Sullivan
Visit website